U.S. Sen. Chuck Grassley (R-Iowa), after meeting with 340B hospital employees in his home state, tweeted that he needs answers about drug company 340B violations and actions HHS may take.

As UCB Reviews HRSA’s 340B Enforcement Letter, Grassley Presses OIG for Answers

Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.

“At UCB, we support a competitive, value-based system that will improve access and affordability for all patients and enable access to UCB’s medicines for vulnerable and underserved populations, including those served by the 340B program,” the company told 340B Report Tuesday night.

Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer